Opinion|Videos|June 24, 2024
Extended Follow Up of KEYNOTE-B61
Author(s)Martin H. Voss, MD, Moshe Ornstein, MD
Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.
Advertisement
Episodes in this series
- Please discuss extended follow up from the phase 2 KEYNOTE-B61 study investigating pembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC. (
Voss M et al. ASCO GU 2024, Abstract #2 )
- Please provide a brief background surrounding KEYNOTE-B61 (
Albiges, et al. Lancet Oncol, 2023 ) - How did the response rates compare across histologies?
- Considering the observed OS benefit with adjuvant pembro, do you intend to approach its adjuvant use in a similar or different manner in this treatment setting?
Advertisement
Related to this article
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
Ulrich Steidl, MD, PhD, has finalized his Montefiore Einstein Comprehensive Cancer Center senior leadership team.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5